Rituxan rituximab: Phase II; marketed to treat low-grade non-Hodgkin's lymphoma (NHL)

IDPH and partners DNA and ROCZ reported positive preliminary results in a

Read the full 129 word article

How to gain access

Continue reading with a
two-week free trial.